Dermata Therapeutics Inc stock is traded at $0.5095, with a volume of 26,595. It is down -4.23% in the last 24 hours and down -41.43% over the past month. Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Previous Close:
$0.532
Open:
$0.5319
24h Volume:
26,595
Relative Volume:
0.44
Market Cap:
$2.51M
Revenue:
-
Net Income/Loss:
-$7.10M
P/E Ratio:
-
EPS:
-$5.31
Net Cash Flow:
-$8.30M
1W Performance:
-17.98%
1M Performance:
-41.43%
6M Performance:
-59.24%
1Y Performance:
-79.62%
1-Day Range:
$0.5004$0.547
1-Week Range:
$0.5004$0.68
52-Week Range:
$0.5004$4.66
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(858)-223-0882Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS